XNASIOVA
Market cap2.26bUSD
Dec 24, Last price
7.43USD
1D
-0.40%
1Q
-19.41%
Jan 2017
6.91%
IPO
-94.06%
Name
Iovance Biotherapeutics Inc
Chart & Performance
Profile
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 1,189 | |||||||||
Cost of revenue | 461,748 | 420,013 | 356,683 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (460,559) | (420,013) | (356,683) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (3,479) | (5,970) | (14,431) | |||||||
Tax Rate | ||||||||||
NOPAT | (457,080) | (414,043) | (342,252) | |||||||
Net income | (444,037) 13.88% | (389,923) 18.94% | (327,821) 27.45% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 463,281 | 190,150 | 239,854 | |||||||
BB yield | -24.24% | -18.68% | -8.19% | |||||||
Debt | ||||||||||
Debt current | 15,554 | 12,587 | 5,057 | |||||||
Long-term debt | 142,947 | 168,892 | 137,005 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | (121,366) | (296,796) | (545,524) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (361,820) | (292,757) | (227,941) | |||||||
CAPEX | (22,290) | (20,425) | (37,574) | |||||||
Cash from investing activities | (155,242) | 256,455 | 132 | |||||||
Cash from financing activities | 462,959 | 190,150 | 239,268 | |||||||
FCF | (455,378) | (422,369) | (398,258) | |||||||
Balance | ||||||||||
Cash | 279,867 | 471,845 | 595,998 | |||||||
Long term investments | 6,430 | 91,588 | ||||||||
Excess cash | 279,808 | 478,275 | 687,586 | |||||||
Stockholders' equity | (2,009,835) | (1,569,229) | (1,173,036) | |||||||
Invested Capital | 2,678,087 | 2,154,313 | 1,866,226 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 235,131 | 159,259 | 153,406 | |||||||
Price | 8.13 27.23% | 6.39 -66.53% | 19.09 -58.86% | |||||||
Market cap | 1,911,615 87.84% | 1,017,665 -65.25% | 2,928,521 -54.36% | |||||||
EV | 1,790,252 | 720,872 | 2,383,000 | |||||||
EBITDA | (427,432) | (398,878) | (342,703) | |||||||
EV/EBITDA | ||||||||||
Interest | 2,985 | |||||||||
Interest/NOPBT |